An extended release formulation of molindone shows promise as an adjunctive treatment for refractory impulsive aggression among children administered stimulant monotherapy for ADHD.
Verapamil adjuvant therapy showed no benefit versus placebo in patients with refractory epilepsy on standard antiepileptic drug (AED) treatment
DMF was associated with lower annualized relapse rates (ARR) and improvement on patient reported outcomes (PROs) in patients with relapsing multiple sclerosis (RMS) who switch to DMF following suboptimal response to glatiramer acetate (GA).
Patients with relapsing-remitting multiple sclerosis (MS) had fewer relapses after switching from glatiramer acetate to fingolimod versus remaining on the injectable disease-modifying therapy
In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium.
Delayed-release dimethyl fumarate (DMF) is associated with better control of multiple sclerosis (MS)-associated declines in work productivity than the injectable platform therapies
At 12 months, patients with relapsing-remitting multiple sclerosis (MS) treated with dimethyl fumarate and fingolimod had similar rates of overall efficacy and adherence, but patients discontinued dimethyl fumigate earlier than fingolimod.
In the "real world," patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were higher than those observed in clinical trials.
Most patients on first-line anti-epileptic drug (AED) monotherapy continue initial treatment for nearly 1.5 years, according to a retrospective database study reported at the 68th AAN Annual Meeting.
The advantages of fingolimod over injectable disease-modifying therapies (iDMTs) in patient retention and treatment satisfaction support use of fingolimod in early relapsing-remitting multiple sclerosis (MS) in the real world.
Treatment of acute migraine with AVP-825, an investigational Breath-Powered Bi-Directional intranasal delivery system containing sumatriptan powder 22mg, resulted in higher rates of total migraine freedom.
IncobotulinumtoxinA injections customized by site and dose improved hand and forearm tremor symptoms patients with Parkinson's disease without increasing hand weakness
Levodopa-carbidopa intestinal gel is safe and effective in Japanese, Taiwanese, and Korean patients with advanced Parkinson's disease
Durlaza, an extended-release aspirin formulation, provides "sustained antiplatelet effects over 24 hours" in patients with type 2 diabetes mellitus (T2DM).
For both smokers and nonsmokers, adding clopidogrel to aspirin therapy is associated with a reduced risk of second stroke in the 90 days following a stroke or high-risk transient ischemic attack (TIA)—but that association is much stronger among smokers
Data from patients with relapsing-remitting multiple sclerosis (MS) who received the humanized monoclonal antibody daclizumab high-yield process (HYP) "extend previous observations" on the agent's rapid pharmacodynamic effects on CD56bright natural killer (NK) cells and regulatory T-cells (Tregs) at treatment initiation, providing additional evidence for an immunomodulatory effect.
Parkinson's disease (PD) "off"-period symptoms control is better following administration of an inhaled levodopa powder formulation (CVT-301) than placebo.
Dietary sodium intake is not associated with MS risk in a prospective cohort of women from the Nurses' Health Study and Nurses' Health Study II
Individual neurocognitive treatment-emergent adverse events (TEAEs) appear to be relatively infrequent among patients administered USL255 (Qudexy® XR [topiramate] extended-release capsules) for refractory partial-onset seizures (POS).
Use of the norepinephrine oral prodrug, droxidopa, for the treatment of symptomatic neurogenic orthostatic hypotension is effective and "generally well tolerated across a range of ages," including in those 75 years and older.
Deflazacort and prednisone improved biomarkers of muscle breakdown versus placebo in boys with Duchenne muscular dystrophy, according to results of a randomized Phase 3 study reported at the 68th AAN Annual Meeting.
Women with >1 eclamptic seizure were more likely to receive an AED, especially if the first seizure occurred postpartum.
Suvorexant (20mg/15mg and 40mg/30mg) improves sleep for patients with insomnia and reduces the impacts of insomnia on patients' daytime functioning, as assessed using the Insomnia Severity Index questionnaire.
Use of lacosamide as the last antiepileptic drug (AED) a patient is administered for status epilepticus (SE) is "strongly associated with termination of status."
Once-daily valbenazine 25 to 75mg for 6 weeks significantly reduced severity of tardive dyskinesia in patients with schizophrenia, schizoaffective disorder, depression, and bipolar disorder.
The "most comprehensive clinical description of antibiotic-associated encephalopathy" has found that "different antibiotics likely have varying patterns of toxicity," a review has found.
No difference in serum vitamin D levels was found between patients with multiple sclerosis (MS) and positive anti-drug antibodies (ADA) vs negative ADA in samples taken 1 year after interferon-β treatment was initiated.
A post-hoc analysis of pooled data from 2 clinical trials showed that teriflunomide use is associated with reduced disability progression after MS relapse, compared to placebo. The findings were presented at the 68th AAN Annual Meeting.
Patients with active relapsing-remitting multiple sclerosis (MS) who had an inadequate response to one or more prior therapies at baseline showed durable improvement in clinical efficacy with alemtuzumab at 5 years.
Topiramate may increase risk of developing psychiatric comorbidities in people with epilepsy when compared with valproate, carbamazepine, lamotrigine, and levetiracetam, all of which may lower risk, according to study results reported at the 68th AAN Annual Meeting.